Table 2 Salivary anti-Pnc PS IgA antibodies in the PncOMPC, PncOMPC+PncPS booster and control groups; number and the percentage of positive samples at the age of 7 and 13 months.
Pnc serotype | Age | IgA | |||
|---|---|---|---|---|---|
PncOMPC group | Control group | ||||
N, samples | Number positive (%) | N, samples | Number positive (%) | ||
6B | 7 mo | 56 | 17 (30) | 55 | 9 (16) |
13 mo (PncOMPC booster) | 45 | 23 (51) | 55 | 26 (47) | |
13 mo (PncPS booster) | 7 | 5 (71) | NA | ||
14 | 7 mo | 56 | 23 (41) | 55 | 14 (25) |
13 mo (PncOMPC booster) | 45 | 19 (42) | 55 | 16 (29) | |
13 mo (PncPS booster) | 7 | 5 (71) | NA | ||
19F | 7 mo | 56 | 32 (57)a | 55 | 17 (31) |
13 mo (PncOMPC booster) | 45 | 35 (78) | 55 | 35 (64) | |
13 mo (PncPS booster) | 7 | 7 (100) | NA | ||
23F | 7 mo | 56 | 11 (20) | 55 | 3 (5) |
13 mo (PncOMPC booster) | 45 | 18 (40) | 55 | 17 (31) | |
13 mo (PncPS booster) | 7 | 5 (71) | NA | ||